CG Oncology Stock Jumps 20% After Stronger-Than-Expected Third Quarter
CG Oncology shares rose 20% to $77.96 after its third-quarter loss narrowed more than analysts forecast and revenue beat estimates. Source: Dow Jones Newswires.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Shares of CG Oncology, a cancer treatment developer, climbed 20% to $77.96 on Friday, according to Dow Jones Newswires. The move followed a third-quarter report in which both revenue and loss per share landed above market expectations.
The company posted a loss of $56.9 million, or 64 cents per share, against a loss of $43.8 million, or 57 cents, a year earlier. Analysts had penciled in a loss of 84 cents per share, so the actual figure came in well ahead of forecasts. Revenue reached $1.6 million, slightly below the $1.7 million of a year before, yet it still topped the $500,000 that analysts anticipated.
The company said it expects to share data from studies in November and December. In October it also named Isabel Kalofonos as Chief Commercial Officer. The stock is up 87% so far this year.
why it matters
For a cancer treatment developer that is still posting losses, a smaller loss and revenue above forecasts often point to tighter cost control. Study data due in November and December will be the next key event for investors, so the shares are likely to stay sensitive to trial news.
market impact
CG Oncology shares: results ahead of expectations support the stock
- CG Oncology shares pressure up — smaller-than-expected loss and revenue above forecasts
tags
instruments
sources
- CG Oncology Shares Rise on Third Quarter Beat — Dow Jones Newswires, 6 November 2026 at 17:45 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗